ME Therapeutics Holdings Inc. Announces Upcoming Participation in the 2024 Bloom Burton & Co Health Care Conference and Interview On CSE TV
ME Therapeutics Holdings Inc. Announces Upcoming Participation in the 2024 Bloom Burton & Co Health Care Conference and Interview On CSE TV
Vancouver, British Columbia--(Newsfile Corp. - March 26, 2024) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of immuno-oncology, is pleased to announce that the Company's CEO, Dr. Salim Dhanji, will attend and participate in one-on-one meetings at the 2024 Bloom Burton & Co. Healthcare Investor Conference scheduled to take place at the Metro Toronto Convention Centre in Toronto from April 16-17, 2024.
不列顛哥倫比亞省溫哥華--（Newsfile Corp.，2024年3月26日）——從事免疫腫瘤學領域新型抗癌藥物的臨床前階段生物技術公司ME Therapeutics Holdings Inc.（CSE：METX）（FSE：Q9T）很高興地宣佈，該公司首席執行官薩利姆·丹吉博士將出席並參加2024年布魯姆·伯頓公司的一對一會議。醫療保健投資者會議定於2024年4月16日至17日在多倫多大多倫多會議中心舉行。
The Company is also pleased to announce the publication of an interview by the Company's CEO, Dr. Salim Dhanji on CSE TV. The interview provides a general background and introduction to the Company and it's research and development focus. The interview can be found at .
公司還高興地宣佈，公司首席執行官薩利姆·丹吉博士在CSE TV上發表了採訪。訪談概述了公司及其研發重點的背景和介紹。訪談可以在以下網址找到。
"After years of focussing on our research and development we are excited to focus more attention on increasing our exposure to potential future investors as we advance our exciting myeloid targeted immuno-oncology research." - Salim Dhanji, PhD, CEO.
“經過多年的專注於研究和開發，隨着我們推進令人興奮的髓系靶向免疫腫瘤學研究，我們很高興能將更多精力集中在增加對潛在未來投資者的敞口上。”-首席執行官薩利姆·丹吉博士。
ME Therapeutics Holdings Inc.
ME Therapeutics 控股公司
Myeloid Enhancement (ME) Therapeutics is an early stage Vancouver based biotechnology company involved in the discovery and development of novel immuno-oncology therapeutics targeting immune suppression in cancer. Our main focus is on overcoming the suppressive effects of an important class of immune cells called myeloid cells in order to enhance anti-cancer immunity. For more information, please visit and the Company's profile on SEDAR+ at .
Myeloid Enhancement（ME）Therapeutics是一家位於溫哥華的早期生物技術公司，參與發現和開發針對癌症免疫抑制的新型免疫腫瘤學療法。我們的主要重點是克服一類名爲骨髓細胞的重要免疫細胞的抑制作用，以增強抗癌免疫力。欲了解更多信息，請訪問SEDAR+上的公司簡介，網址爲。
ON BEHALF OF THE BOARD
代表董事會
"Salim Dhanji"
Dr. Salim Dhanji, PhD
Chief Executive Officer and Director
“薩利姆·丹吉“
薩利姆·丹吉博士，博士
首席執行官兼董事
For further information, please contact:
Dr. Salim Dhanji
Telephone: (236) 516-7714
欲了解更多信息，請聯繫：
薩利姆·丹吉博士
電話：(236) 516-7714
譯文內容由第三人軟體翻譯。